Novel therapeutics for brain tumors: current practice and future prospects

References

• Gupta A, Dwivedi T. A simplified overview of world health organization classification update of central nervous system tumors 2016. J Neurosci Rural Pract. 2017;8(4):629–641.
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009;110(3):583–588.
   PubMed Web of Science ®Google Scholar
• Woodworth GF, Dunn GP, Nance EA, et al. Emerging insights into barriers to effective brain tumor therapeutics. Front Oncol. 2014;4:126.
   PubMedGoogle Scholar
• Vellimana AK, Recinos VR, Hwang L, et al. Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model. J Neurooncol. 2013;111(3):229–236.
   PubMed Web of Science ®Google Scholar
• Tyler B, Fowers KD, Li KW, et al. A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats. J Neurosurg. 2010;113(2):210–217.
   PubMed Web of Science ®Google Scholar
• Amini MA, Abbasi AZ, Cai P, et al. Combining tumor microenvironment modulating nanoparticles with doxorubicin to enhance chemotherapeutic efficacy and boost antitumor immunity. J Natl Cancer Inst. 2019;111(4):399–408.
   PubMedGoogle Scholar
• Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21(5):387–422.
   PubMed Web of Science ®Google Scholar
• Jahangiri A, Chin AT, Flanigan PM, et al. Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg. 2017;126(1):191–200.
   PubMed Web of Science ®Google Scholar
• Kwiatkowska A, Nandhu MS, Behera P, et al. Strategies in gene therapy for glioblastoma. Cancers (Basel). 2013;5(4):1271–1305.
   PubMedGoogle Scholar
• Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4(5):346–358.
   PubMed Web of Science ®Google Scholar
• Pack DW, Hoffman AS, Pun S, et al. Design and development of polymers for gene delivery. Nat Rev Drug Discov. 2005;4(7):581–593.
   PubMed Web of Science ®Google Scholar
• Mao H, Lebrun DG, Yang J, et al. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest. 2012;30(1):48–56.
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170(5):1445–1453.
   PubMed Web of Science ®Google Scholar
• Kakimi K, Karasaki T, Matsushita H, et al. Advances in personalized cancer immunotherapy. Breast Cancer. 2017;24(1):16–24.
   PubMed Web of Science ®Google Scholar
• Gubens MA, Davies M. NCCN guidelines updates: new immunotherapy strategies for improving outcomes in non-small cell lung cancer. J Natl Compr Canc Netw. 2019;17(5.5):574–578.
   PubMed Web of Science ®Google Scholar
• Preusser M, Lim M, Hafler DA, et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015;11(9):504–514.
   PubMed Web of Science ®Google Scholar
• Almutairi MM Gong, C, Xu, YG, et al. Factors controlling permeability of the blood-brain barrier. Cell Mol Life Sci. 2016;73(1):57–77.
   PubMed Web of Science ®Google Scholar
• Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci. 2000;89(11):1371–1388.
   PubMed Web of Science ®Google Scholar
• Bhowmik A, Khan R, Ghosh MK. Blood brain barrier: a challenge for effectual therapy of brain tumors. Biomed Res Int. 2015;2015:320941.
   PubMed Web of Science ®Google Scholar
• Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des. 2004;10(12):1295–1312.
   PubMed Web of Science ®Google Scholar
• Armulik A, Genové G, Mäe M, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468(7323):557–561.
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7(1):41–53.
   PubMed Web of Science ®Google Scholar
• Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1):a020412.
   PubMed Web of Science ®Google Scholar
• Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol. 2000;2(1):45–59.
   PubMed Web of Science ®Google Scholar
• van Tellingen O, Yetkin-Arik B, de Gooijer MC, et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015;19:1–12.
   PubMed Web of Science ®Google Scholar
• Zhou W, Chen C, Shi Y, et al. Targeting glioma stem cell-derived pericytes disrupts the blood-tumor barrier and improves chemotherapeutic efficacy. Cell Stem Cell. 2017;21(5):591–603.e4.
   PubMed Web of Science ®Google Scholar
• Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA. 1994;91(6):2076–2080.
   PubMed Web of Science ®Google Scholar
• Mehta AM, Sonabend AM, Bruce JN. Convection-enhanced delivery. Neurotherapeutics. 2017;14(2):358–371.
   PubMed Web of Science ®Google Scholar
• Raghavan R, Brady ML, Rodríguez-Ponce MI, et al. Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus. 2006;20(4):E12.
   PubMedGoogle Scholar
• Sampson JH, Brady ML, Petry NA, et al. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery. 2007;60(2 Suppl 1):ONS89–98. discussion ONS98–9.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Akabani G, Archer GE, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 2008;10(3):320–329.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer G, Pedain C, et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg. 2010;113(2):301–309.
   PubMed Web of Science ®Google Scholar
• Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg. 2004;100(3):472–479.
   PubMed Web of Science ®Google Scholar
• Young JS, Bernal G, Polster SP, et al. Convection-enhanced delivery of polymeric nanoparticles encapsulating chemotherapy in canines with spontaneous supratentorial tumors. World Neurosurg. 2018;117:e698–e704.
   PubMed Web of Science ®Google Scholar
• Zhang C, Nance EA, Mastorakos P, et al. Convection enhanced delivery of cisplatin-loaded brain penetrating nanoparticles cures malignant glioma in rats. J Control Release. 2017;263:112–119.
   PubMed Web of Science ®Google Scholar
• White E, Bienemann A, Pugh J, et al. An evaluation of the safety and feasibility of convection-enhanced delivery of carboplatin into the white matter as a potential treatment for high-grade glioma. J Neurooncol. 2012;108(1):77–88.
   PubMed Web of Science ®Google Scholar
• White E, Bienemann A, Taylor H, et al. A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme. Contemp Clin Trials. 2012;33(2):320–331.
   PubMed Web of Science ®Google Scholar
• Arshad A, Yang B, Bienemann AS, et al. Convection-enhanced delivery of carboplatin PLGA nanoparticles for the treatment of glioblastoma. PLoS One. 2015;10(7):e0132266.
   PubMed Web of Science ®Google Scholar
• Shi M, Anantha M, Wehbe M, et al. Liposomal formulations of carboplatin injected by convection-enhanced delivery increases the median survival time of F98 glioma bearing rats. J Nanobiotechnology. 2018;16(1):77.
   PubMedGoogle Scholar
• Huo T, Barth RF, Yang W, et al. Preparation, biodistribution and neurotoxicity of liposomal cisplatin following convection enhanced delivery in normal and F98 glioma bearing rats. PLoS One. 2012;7(11):e48752.
   PubMed Web of Science ®Google Scholar
• Nordling-David MM, Yaffe R, Guez D, et al. Liposomal temozolomide drug delivery using convection enhanced delivery. J Control Release. 2017;261:138–146.
   PubMed Web of Science ®Google Scholar
• Sewing ACP, Lagerweij T, van Vuurden DG, et al. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma. J Neurosurg Pediatr. 2017;19(5):518–530.
   PubMed Web of Science ®Google Scholar
• Barua NU, Hopkins K, Woolley M, et al. A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastoma. Drug Deliv. 2016;23(1):167–173.
   PubMed Web of Science ®Google Scholar
• Vogelbaum MA, Brewer C, Barnett GH, et al. First-in-human evaluation of the cleveland multiport catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: results of pilot trial 1. J Neurosurg. 2018;1–10.
   PubMed Web of Science ®Google Scholar
• Barua NU, Gill SS, Love S. Convection-enhanced drug delivery to the brain: therapeutic potential and neuropathological considerations. Brain Pathol. 2014;24(2):117–127.
   PubMed Web of Science ®Google Scholar
• Nandhu MS, Kwiatkowska A, Bhaskaran V, et al. Tumor-derived fibulin-3 activates pro-invasive NF-kappaB signaling in glioblastoma cells and their microenvironment. Oncogene. 2017;36(34):4875–4886.
   PubMed Web of Science ®Google Scholar
• Tobias A, Ahmed A, Moon K-S, et al. The art of gene therapy for glioma: a review of the challenging road to the bedside. J Neurol Neurosurg Psychiatry. 2013;84(2):213–222.
   PubMed Web of Science ®Google Scholar
• Guerrero-Cazares H, Tzeng SY, Young NP, et al. Biodegradable polymeric nanoparticles show high efficacy and specificity at DNA delivery to human glioblastoma in vitro and in vivo. ACS Nano. 2014;8(5):5141–5153.
   PubMed Web of Science ®Google Scholar
• Lynn DM, Anderson DG, Putnam D, et al. Accelerated discovery of synthetic transfection vectors: parallel synthesis and screening of a degradable polymer library. J Am Chem Soc. 2001;123(33):8155–8156.
   PubMed Web of Science ®Google Scholar
• Tzeng SY, Higgins LJ, Pomper MG, et al. Student award winner in the Ph.D. category for the 2013 society for biomaterials annual meeting and exposition, april 10–13,2013, Boston, Massachusetts: biomaterial-mediated cancer-specific DNA delivery to liver cell cultures using synthetic poly(beta-amino ester)s. J Biomed Mater Res A. 2013;101(7):1837–1845.
   PubMed Web of Science ®Google Scholar
• Idbaih A, Erbs P, Foloppe J, et al. TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma. J Clin Oncol. 2017;35(15_suppl):e13510–e13510.
   Google Scholar
• Tamargo RJ, Myseros JS, Epstein JI, et al. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res. 1993;53(2):329–333.
   PubMed Web of Science ®Google Scholar
• Yang MB, Tamargo RJ, Brem H. Controlled delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer. Cancer Res. 1989;49(18):5103–5107.
   PubMed Web of Science ®Google Scholar
• Fung LK, Shin M, Tyler B, et al. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm Res. 1996;13(5):671–682.
   PubMed Web of Science ®Google Scholar
• Sipos EP, Tyler B, Piantadosi S, et al. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol. 1997;39(5):383–389.
   PubMed Web of Science ®Google Scholar
• Grossman SA, Reinhard C, Colvin OM, et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg. 1992;76(4):640–647.
   PubMed Web of Science ®Google Scholar
• Brem H, Mahaley MS, Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg. 1991;74(3):441–446.
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet. 1995;345(8956):1008–1012.
   PubMed Web of Science ®Google Scholar
• Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery. 1997;41(1):44–48. discussion 48–9.
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79–88.
   PubMed Web of Science ®Google Scholar
• Mangraviti A, Tyler B, Brem H. Interstitial chemotherapy for malignant glioma: future prospects in the era of multimodal therapy. Surg Neurol Int. 2015;6(Suppl 1):S78–84.
   PubMedGoogle Scholar
• Pallud J, Audureau E, Noel G, et al. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. Neuro Oncol. 2015;17(12):1609–1619.
   PubMed Web of Science ®Google Scholar
• Chowdhary SA, Ryken T, Newton HB. Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. J Neurooncol. 2015;122(2):367–382.
   PubMed Web of Science ®Google Scholar
• Xing WK, Shao C, Qi Z-Y, et al. The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis. Drug Des Devel Ther. 2015;9:3341–3348.
   PubMed Web of Science ®Google Scholar
• Fountzilas G, Karavelis A, Capizzello A, et al. Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study. J Neurooncol. 1999;45(2):159–165.
   PubMed Web of Science ®Google Scholar
• Prados MD, Schold SC, Spence AM, et al. Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol. 1996;14(8):2316–2321.
   PubMed Web of Science ®Google Scholar
• Walter KA, Cahan MA, Gur A, et al. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res. 1994;54(8):2207–2212.
   PubMed Web of Science ®Google Scholar
• Li KW, Dang W, Tyler BM, et al. Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies. Clin Cancer Res. 2003;9(9):3441–3447.
   PubMed Web of Science ®Google Scholar
• Pradilla G, Wang PP, Gabikian P, et al. Local intracerebral administration of Paclitaxel with the paclimer delivery system: toxicity study in a canine model. J Neurooncol. 2006;76(2):131–138.
   PubMed Web of Science ®Google Scholar
• Lesniak MS, Upadhyay U, Goodwin R, et al. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res. 2005;25(6b):3825–3831.
   PubMed Web of Science ®Google Scholar
• Mangraviti A, Raghavan T, Volpin F, et al. HIF-1alpha- targeting acriflavine provides long term survival and radiological tumor response in brain cancer therapy. Sci Rep. 2017;7(1):14978.
   PubMedGoogle Scholar
• Charest G, Sanche L, Fortin D, et al. Glioblastoma treatment: bypassing the toxicity of platinum compounds by using liposomal formulation and increasing treatment efficiency with concomitant radiotherapy. Int J Radiat Oncol Biol Phys. 2012;84(1):244–249.
   PubMed Web of Science ®Google Scholar
• Papachristodoulou A, Signorell RD, Werner B, et al. Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes. J Control Release. 2019;295:130–139.
   PubMed Web of Science ®Google Scholar
• Vanza J, Jani P, Pandya N, et al. Formulation and statistical optimization of intravenous temozolomide-loaded PEGylated liposomes to treat glioblastoma multiforme by three-level factorial design. Drug Dev Ind Pharm. 2018;44(6):923–933.
   PubMed Web of Science ®Google Scholar
• Lin C-Y, Li R-J, Huang C-Y, et al. Controlled release of liposome-encapsulated temozolomide for brain tumour treatment by convection-enhanced delivery. J Drug Target. 2018;26(4):325–332.
   PubMed Web of Science ®Google Scholar
• Sun X, Pang Z, Ye H, et al. Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome. Biomaterials. 2012;33(3):916–924.
   PubMed Web of Science ®Google Scholar
• Yuan BO, Zhao Y, Dong S, et al. Cell-penetrating peptide-coated liposomes for drug delivery across the blood-brain barrier. Anticancer Res. 2019;39(1):237–243.
   PubMed Web of Science ®Google Scholar
• Lin Q, Mao K-L, Tian F-R, et al. Brain tumor-targeted delivery and therapy by focused ultrasound introduced doxorubicin-loaded cationic liposomes. Cancer Chemother Pharmacol. 2016;77(2):269–280.
   PubMed Web of Science ®Google Scholar
• Steiniger SCJ, Kreuter J, Khalansky AS, et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer. 2004;109(5):759–767.
   PubMed Web of Science ®Google Scholar
• DuVall GA, Tarabar D, Seidel RH, et al. Phase 2: a dose-escalation study of OncoGel (ReGel/paclitaxel), a controlled-release formulation of paclitaxel, as adjunctive local therapy to external-beam radiation in patients with inoperable esophageal cancer. Anticancer Drugs. 2009;20(2):89–95.
   PubMed Web of Science ®Google Scholar
• Lei C, Davoodi P, Zhan W, et al. Development of nanoparticles for drug delivery to brain tumor: the effect of surface materials on penetration into brain tissue. J Pharm Sci. 2019;108(5):1736–1745.
   PubMed Web of Science ®Google Scholar
• Sun X, Chen Y, Zhao H, et al. Dual-modified cationic liposomes loaded with paclitaxel and survivin siRNA for targeted imaging and therapy of cancer stem cells in brain glioma. Drug Deliv. 2018;25(1):1718–1727.
   PubMed Web of Science ®Google Scholar
• Ganipineni LP, Ucakar B, Joudiou N, et al. Magnetic targeting of paclitaxel-loaded poly(lactic-co-glycolic acid)-based nanoparticles for the treatment of glioblastoma. Int J Nanomedicine. 2018;13:4509–4521.
   PubMed Web of Science ®Google Scholar
• Li M, Zhang F, Su Y, et al. Nanoparticles designed to regulate tumor microenvironment for cancer therapy. Life Sci. 2018;201(March 22):37–44.
   PubMedGoogle Scholar
• Stupp R, Mason WP, van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Brem S, Tyler B, Li K, et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol. 2007;60(5):643–650.
   PubMed Web of Science ®Google Scholar
• Recinos VR, Tyler BM, Bekelis K, et al. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Neurosurgery. 2010;66(3):530–537. discussion 537.
   PubMed Web of Science ®Google Scholar
• Zhang YH, Zhang H, Liu J-M, et al. Temozolomide/PLGA microparticles: a new protocol for treatment of glioma in rats. Med Oncol. 2011;28(3):901–906.
   PubMed Web of Science ®Google Scholar
• Shapira-Furman T, Serra R, Gorelick N, et al. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer. J Control Release. 2019;295:93–101.
   PubMed Web of Science ®Google Scholar
• DiMeco F, Li KW, Tyler BM, et al. Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J Neurosurg. 2002;97(5):1173–1178.
   PubMed Web of Science ®Google Scholar
• Ferroli P, Broggi M, Franzini A, et al. Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note. Neurosurgery. 2006;59(2):E433–4. discussion E433–4.
   PubMedGoogle Scholar
• Yemisci M, Bozdag S, Cetin M, et al. Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres. Neurosurgery. 2006;59(6):1296–1302. discussion 1302–1303.
   PubMed Web of Science ®Google Scholar
• Boiardi A, Silvani A, Eoli M, et al. Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival? J Neurooncol. 2008;88(1):105–113.
   PubMed Web of Science ®Google Scholar
• Lam P, Lin R, Steinmetz NF. Delivery of mitoxantrone using a plant virus-based nanoparticle for the treatment of glioblastomas. J Mater Chem B. 2018;6(37):5888–5895.
   PubMed Web of Science ®Google Scholar
• Chen Q, Liu L, Lu Y, et al. Tumor microenvironment-triggered aggregated magnetic nanoparticles for reinforced image-guided immunogenic chemotherapy. Adv Sci (Weinh). 2019;6(6):1802134.
   PubMedGoogle Scholar
• Li Y, Wu M, Zhang N, et al. Mechanisms of enhanced antiglioma efficacy of polysorbate 80-modified paclitaxel-loaded PLGA nanoparticles by focused ultrasound. J Cell Mol Med. 2018;22(9):4171–4182.
   PubMed Web of Science ®Google Scholar
• Wu J, Chen J, Feng Y, et al. Tumor microenvironment as the “regulator” and “target” for gene therapy. J Gene Med. 2019;21:e3088.
   PubMed Web of Science ®Google Scholar
• Benos L, Spyrou LA, Sarris IE. Development of a new theoretical model for blood-CNTs effective thermal conductivity pertaining to hyperthermia therapy of glioblastoma multiform. Comput Methods Programs Biomed. 2019;172:79–85.
   PubMed Web of Science ®Google Scholar
• Chastagner P, Sudour H, Mriouah J, et al. Preclinical studies of pegylated- and non-pegylated liposomal forms of doxorubicin as radiosensitizer on orthotopic high-grade glioma xenografts. Pharm Res. 2015;32(1):158–166.
   PubMed Web of Science ®Google Scholar
• Zou L, Tao Y, Payne G, et al. Targeted delivery of nano-PTX to the brain tumor-associated macrophages. Oncotarget. 2017;8(4):6564–6578.
   PubMedGoogle Scholar
• Kang T, Jiang M, Jiang D, et al. Enhancing glioblastoma-specific penetration by functionalization of nanoparticles with an iron-mimic peptide targeting transferrin/transferrin receptor complex. Mol Pharm. 2015;12(8):2947–2961.
   PubMedGoogle Scholar
• Zhang Y, Zhai M, Chen Z, et al. Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma. Drug Deliv. 2017;24(1):1045–1055.
   PubMed Web of Science ®Google Scholar
• Smith SJ, Tyler BM, Gould T, et al. Overall survival in malignant glioma is significantly prolonged by neurosurgical delivery of etoposide and temozolomide from a thermo-responsive biodegradable paste. Clin Cancer Res. 2019.
   Web of Science ®Google Scholar
• Stupp R, Lukas RV, Hegi ME. Improving survival in molecularly selected glioblastoma. Lancet. 2019;393(10172):615–617.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Chang YH, Rajesh R. Targeted delivery of etoposide, carmustine and doxorubicin to human glioblastoma cells using methoxy poly(ethylene glycol)poly(epsiloncaprolactone) nanoparticles conjugated with wheat germ agglutinin and folic acid. Mater Sci Eng C Mater Biol Appl. 2019;96:114–128.
   PubMed Web of Science ®Google Scholar
• Emamgholizadeh Minaei S, Khoei S, Khoee S, et al. Tri-block copolymer nanoparticles modified with folic acid for temozolomide delivery in glioblastoma. Int J Biochem Cell Biol. 2019;108:72–83.
   PubMed Web of Science ®Google Scholar
• Wang C, Jiang M, Hou H, et al. Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma. Oncol Lett. 2018;16(5):5607–5614.
   PubMed Web of Science ®Google Scholar
• Nile DL, Rae C, Hyndman IJ, et al. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. BMC Cancer. 2016;16:621.
   PubMed Web of Science ®Google Scholar
• Han S, Wang C, Qin X, et al. LPS alters the immuno-phenotype of glioma and glioma stem-like cells and induces in vivo antitumor immunity via TLR4. J Exp Clin Cancer Res. 2017;36(1):83.
   PubMedGoogle Scholar
• De Waele J, Routh ED, Pullikuth A, et al. Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade. Oncoimmunology. 2018;7(3):e1407899.
   PubMed Web of Science ®Google Scholar
• Mathios D, Kim JE, Mangraviti A, et al. Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci Transl Med. 2016;8(370):370ra180.
   PubMed Web of Science ®Google Scholar
• Ohkuri T, Sevko A, Heide J, et al. Protective role of STING against gliomagenesis: rational use of STING agonist in anti-glioma immunotherapy. Oncoimmunology. 2015;4(4):e999523.
   PubMed Web of Science ®Google Scholar
• Ohkuri T, Ghosh A, Kosaka A, et al. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res. 2014;2(12):1199–1208.
   PubMed Web of Science ®Google Scholar
• Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11(15):5515–5525.
   PubMed Web of Science ®Google Scholar
• Prosniak M, Harshyne LA, Andrews DW, et al. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin Cancer Res. 2013;19(14):3776–3786.
   PubMed Web of Science ®Google Scholar
• Sharma I, Siraj F, Sharma KC, et al. Immunohistochemical expression of chemokine receptor CXCR3 and its ligand CXCL10 in low-grade astrocytomas and glioblastoma multiforme: A tissue microarray-based comparison. J Cancer Res Ther. 2016;12(2):793–797.
   PubMed Web of Science ®Google Scholar
• Wang P, Peng X, Zhang J, et al. LncRNA-135528 inhibits tumor progression by up-regulating CXCL10 through the JAK/STAT pathway. Apoptosis. 2018;23(11–12):651–666.
   PubMed Web of Science ®Google Scholar
• Hersh DS, Kim AJ, Winkles JA, et al. Emerging applications of therapeutic ultrasound in neuro-oncology: moving beyond tumor ablation. Neurosurgery. 2016;79(5):643–654.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Fomenko A, Lozano AM. Magnetic resonance-guided focused ultrasound: current status and future perspectives in thermal ablation and blood-brain barrier opening. J Korean Neurosurg Soc. 2019;62(1):10–26.
   PubMed Web of Science ®Google Scholar
• Hijnen NM, Heijman E, Köhler MO, et al. Tumour hyperthermia and ablation in rats using a clinical MR-HIFU system equipped with a dedicated small animal set-up. Int J Hyperthermia. 2012;28(2):141–155.
   PubMed Web of Science ®Google Scholar
• Jenne JW, Preusser T, Gunther M. High-intensity focused ultrasound: principles, therapy guidance, simulations and applications. Z Med Phys. 2012;22(4):311–322.
   PubMed Web of Science ®Google Scholar
• Ries M, de Senneville BD, Roujol S, et al. Real-time 3D target tracking in MRI guided focused ultrasound ablations in moving tissues. Magn Reson Med. 2010;64(6):1704–1712.
   PubMed Web of Science ®Google Scholar
• Colen RR, Sahnoune I, Weinberg JS. Neurosurgical applications of high-intensity focused ultrasound with magnetic resonance thermometry. Neurosurg Clin N Am. 2017;28(4):559–567.
   PubMed Web of Science ®Google Scholar
• Mainprize T, Lipsman N, Huang Y, et al. Blood-brain barrier opening in primary brain tumors with non-invasive MR-guided focused ultrasound: a clinical safety and feasibility study. Sci Rep. 2019;9(1):321.
   PubMedGoogle Scholar
• Timbie KF, Afzal U, Date A, et al. MR image-guided delivery of cisplatin-loaded brain-penetrating nanoparticles to invasive glioma with focused ultrasound. J Control Release. 2017;263:120–131.
   PubMed Web of Science ®Google Scholar
• Dong Q, He L, Chen L, et al. Opening the blood-brain barrier and improving the efficacy of temozolomide treatments of glioblastoma using pulsed, focused ultrasound with a microbubble contrast agent. Biomed Res Int. 2018;2018:6501508.
   PubMedGoogle Scholar
• Poon C, McMahon D, Hynynen K. Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasound. Neuropharmacology. 2017;120:20–37.
   PubMed Web of Science ®Google Scholar
• Sun T, Zhang Y, Power C, et al. Closed-loop control of targeted ultrasound drug delivery across the blood-brain/tumor barriers in a rat glioma model. Proc Natl Acad Sci USA. 2017;114(48). E10281-e10290.
   Web of Science ®Google Scholar
• Liu H-L, Hsu P-H, Lin C-Y, et al. Focused ultrasound enhances central nervous system delivery of bevacizumab for malignant glioma treatment. Radiology. 2016;281(1):99–108.
   PubMed Web of Science ®Google Scholar
• Wei KC, Chu P-C, Wang H-YJ, et al. Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study. PLoS One. 2013;8(3):e58995.
   PubMed Web of Science ®Google Scholar